KRAS and cancer: Mutations affecting the KRAS/GTP interface and those targeting the CTNNB1 interfaces with FBXW11 or BTCR are largely mutually exclusive when considering all cancer types (Fig. S7; Table S3c), and particularly for endometrial adenocarcinoma, where both mutations are common.